Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. MedRxiv 2020.10.15.20209817 [Preprint]. 2020 [cited 2020 Nov 18]. Available from: https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1 doi: https://doi.org/10.1101/2020.10.15.20209817
2. Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204-14. Clinicaltrials.gov registration number: NCT02949011.
3. Clinicaltrials.gov [Internet]. Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza. Clinical Trial; [cited 2020 Nov 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT03684044Clinicaltrials.gov Identifier: NCT03684044.
4. Ulbricht C, Basch E, Cheung L, et al. An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the Natural Standard Research Collaboration. Journal of dietary supplements. 2014;11(1):80-120.
5. Zakay-Rones Z, Thom E, Wollan T, Wadstein J. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. J Int Med Res. 2004;32(2):132-40.